Aristo Pharmaceuticals Private Limited — Cefpodoxime Exporter Profile
Indian Pharmaceutical Exporter · #14 for Cefpodoxime · $311.6K export value · DGFT Verified
Aristo Pharmaceuticals Private Limited is the #14 Indian exporter of Cefpodoxime with $311.6K in export value and 48 verified shipments. Aristo Pharmaceuticals Private Limited holds a 0.4% market share in Cefpodoxime exports across 4 countries. The company exports 8 pharmaceutical products worth $19.4M across 8 therapeutic categories.
Aristo Pharmaceuticals Private Limited — Cefpodoxime Export Profile: Buyers & Destinations
Where Does Aristo Pharmaceuticals Private Limited Export Cefpodoxime?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SUDAN | $249.9K | 8 | 83.0% |
| KENYA | $20.4K | 9 | 6.8% |
| CAMBODIA | $18.2K | 9 | 6.0% |
| MALDIVES | $12.7K | 24 | 4.2% |
Aristo Pharmaceuticals Private Limited exports Cefpodoxime to 4 countries. The largest destination is SUDAN accounting for 83.0% of Aristo Pharmaceuticals Private Limited's Cefpodoxime shipments, followed by KENYA (6.8%) and CAMBODIA (6.0%). These destinations reflect Aristo Pharmaceuticals Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Cefpodoxime from Aristo Pharmaceuticals Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| PHARMA TRADING COMPANY BUILDING | SUDAN | $249.9K | 8 |
| IDEAL TRADING ENTERPRISES CO.LTD. | CAMBODIA | $18.0K | 8 |
| SURGILINKS LIMITED | KENYA | $11.7K | 7 |
| ADK PHARMACEUTICAL COMPANY PVT LTD | MALDIVES | $10.0K | 19 |
| SURGILINKS | KENYA | $8.6K | 2 |
| ADK PHARMACEUTICAL COMPANY PVT LTD. | MALDIVES | $2.7K | 5 |
| IDEAL TRADING ENTERPRISES CO., LTD | CAMBODIA | $229 | 1 |
Aristo Pharmaceuticals Private Limited supplies Cefpodoxime to 7 buyers globally. The largest buyer is PHARMA TRADING COMPANY BUILDING (SUDAN), followed by IDEAL TRADING ENTERPRISES CO.LTD. (CAMBODIA) and SURGILINKS LIMITED (KENYA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Cefpodoxime Export Value and How Much Does Aristo Pharmaceuticals Private Limited Contribute?
India exported $33.7M worth of Cefpodoxime through 1,734 shipments from 178 suppliers to 78 countries, serving 442 buyers globally. Aristo Pharmaceuticals Private Limited contributes $311.6K to this total, accounting for 0.4% of India's Cefpodoxime exports. Aristo Pharmaceuticals Private Limited ships Cefpodoxime to 4 countries through 7 buyers.
What Is the Average Shipment Value for Aristo Pharmaceuticals Private Limited's Cefpodoxime Exports?
Aristo Pharmaceuticals Private Limited's average Cefpodoxime shipment value is $6.5K per consignment, based on 48 shipments totaling $311.6K. The largest destination is SUDAN (83.0% of Aristo Pharmaceuticals Private Limited's Cefpodoxime exports).
How Does Aristo Pharmaceuticals Private Limited Compare to Other Indian Cefpodoxime Exporters?
Aristo Pharmaceuticals Private Limited ranks #14 among 178 Indian Cefpodoxime exporters with a 0.4% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($10.9M), LUPIN LIMITED ($10.6M), AUROBINDO PHARMA LIMITED ($4.5M). Aristo Pharmaceuticals Private Limited processed 48 shipments to 4 destination countries.
What Cefpodoxime Formulations Does Aristo Pharmaceuticals Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CEFOD-O 200 CEFPODOXIME PROXETIL TABLETSUSP 200MG BATCH NO. EBPL233634 MFG. DATE 11/2023 EXP. DATE 10/2025 | $98.3K | 2 |
| CEFOD-O 100 DRY SYRUP CEFPODOXIME PROXETIL FOR ORAL SUSPENSION USP Batch No. EBPA240025 & EBPA240026 Mfg. Date 01/202 | $46.2K | 1 |
| CEFOD-O 200 CEFPODOXIME PROXETIL TABLETSUSP 200MG Batch No. EBPL233635 Mfg. Date 11/2023 Exp. Date 10/2025 | $43.8K | 1 |
| SAMPLES CEFOD-O 200 CEFPODOXIME PROXETILTABLETS USP 200MG Batch No. EBPL233634& EBPL233635 Mfg. Date 11/2023 Exp. Dat | $30.7K | 1 |
| CEFOD-O 100 DRY SYRUP CEFPODOXIME PROXETIL FOR ORAL SUSPENSION USP BATCH NO. EBPL233831 MFG. DATE 11/2023 EXP. DATE 10/2 | $21.8K | 2 |
| SAMPLES CEFOD-O 100 DRY SYRUP CEFPODOXIME PROXETIL FOR ORAL SUSPENSION USP Batch No. EBPM234132 Mfg. Date 12/2023 Exp. | $9.2K | 1 |
| HARMLESS MEDICINES: MONOCEF-O 100 DRY SYRUP CEFPODOXIME PROXETIL FOR ORAL SUSPENSION USP BATCH NO. EBPE231596; EBPE231 | $7.2K | 1 |
| MONOCEF-O 200 (CEFPODOXIME PROXETIL TABL | $5.6K | 2 |
| MONOCEF-O 200 (CEFPODOXIME PROXETIL TABLETS USP 200 MG) (250 X 10 X 1 X 10'S = 25000 TBS) | $5.6K | 1 |
| HARMLESS MEDICINES- MONOCEF-O 200 CEFPODOXIME PROXETIL TABLETS USP 200 MG, BATCHNO.EBPA240343 (200X10X1X10'S) MFG. DT.0 | $4.8K | 1 |
Aristo Pharmaceuticals Private Limited exports 36 distinct Cefpodoxime formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CEFOD-O 200 CEFPODOXIME PROXETIL TABLETSUSP 200MG BATCH NO. with 2 shipments worth $98.3K.
How Does Aristo Pharmaceuticals Private Limited Compare to Nearest Cefpodoxime Exporters?
Exporters ranked immediately above and below #14 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | AJANTA PHARMA LIMITED | $330.9K | 46 | 4 | $7.2K |
| 13 | MACLEODS PHARMACEUTICALS LTD | $321.9K | 12 | 3 | $26.8K |
| 14 | ARISTO PHARMACEUTICALS PRIVATE LIMITED ★ | $311.6K | 48 | 4 | $6.5K |
| 15 | SANCE LABORATORIES PRIVATE LIMITED | $303.5K | 18 | 5 | $16.9K |
Aristo Pharmaceuticals Private Limited ranks #14 among 178 Indian Cefpodoxime exporters. Average shipment value of $6.5K compared to the market average of $189.3K. The closest competitors by value are AJANTA PHARMA LIMITED and MACLEODS PHARMACEUTICALS LTD.
Which Indian Ports Ship Cefpodoxime Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 174 | 10.0% |
| SAHAR AIR | 166 | 9.6% |
| JNPT/ NHAVA SHEVA SEA | 133 | 7.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 128 | 7.4% |
| JNPT | 88 | 5.1% |
| DELHI AIR | 81 | 4.7% |
| HYDERABAD ICD | 79 | 4.6% |
| DELHI AIR CARGO ACC (INDEL4) | 78 | 4.5% |
Geopolitical & Trade Policy Impact on Aristo Pharmaceuticals Private Limited's Cefpodoxime Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Aristo Pharmaceuticals. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended delivery times. Major shipping lines have implemented 'Emergency Risk Surcharges,' adding financial strain to exporters relying on these routes. Additionally, the U.S. has imposed tariffs on pharmaceutical imports, affecting the profitability of Indian exporters. However, the India–European Union Free Trade Agreement (FTA), concluded in January 2026, offers a silver lining. The FTA eliminates tariffs on Indian pharmaceutical products entering the EU, potentially boosting exports to this region. Aristo Pharmaceuticals can leverage this agreement to strengthen its presence in the European market, offsetting challenges in other regions.
Aristo Pharmaceuticals Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practices (EU GMP) set stringent quality requirements. While specific compliance details for Aristo Pharmaceuticals are not publicly available, adherence to these standards is essential to maintain market access and credibility. The evolving regulatory landscape necessitates continuous investment in quality assurance and compliance infrastructure to meet the expectations of global markets.
About Aristo Pharmaceuticals Private Limited
Aristo Pharmaceuticals Private Limited exports 8 products worth $19.4M. Beyond Cefpodoxime, top products include Telmisartan, Hydrochlorothiazide, Domperidone, Pioglitazone, Probiotics. View the complete Aristo Pharmaceuticals Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Cefpodoxime — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Cefpodoxime shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Aristo Pharmaceuticals Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 50 individual customs records matching Aristo Pharmaceuticals Private Limited exporting Cefpodoxime, covering 36 formulations to 4 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 78+ countries, 442+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Cefpodoxime Export Data from Aristo Pharmaceuticals Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Aristo Pharmaceuticals Private Limited's Cefpodoxime exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Aristo Pharmaceuticals Private Limited
Full Company Profile →
8 products · $19.4M total trade · 8 categories
Cefpodoxime Stats
Company Overview
Top Products by Aristo Pharmaceuticals Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Aristo Pharmaceuticals Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Cefpodoxime. For current shipment-level data, contact TransData Nexus.